Cédric R.
- Country
- France
- Department
- Hematology
Research Overview
- A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of BGB 21447 in Patients With Mature B-Cell Malignancies
- Phase 1b/2 Study of MK-1045 Monotherapy and MK-1045 Plus Tocilizumab in Adults with Relapsed/Refractory Non‑Hodgkin Lymphoma
- Phase 2/3 Randomized Open‑Label Study of MK‑1045 Combined with Rituximab Versus Standard Chemotherapy Plus Rituximab in First‑Line Follicular Lymphoma
Data & Insights
Has run more than one trial at 31 of 116 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating various forms of lymphoid malignancies, with particular emphasis on B-cell lymphomas. Their clinical expertise encompasses both aggressive and indolent lymphoma subtypes.
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Extranodal Marginal Zone Lymphoma
- MALT Lymphoma
Their therapeutic approach includes exploration of novel antibody-based treatments and combination therapies for lymphoma patients.
Innovative Therapies
The investigator focuses on developing and implementing targeted therapeutic approaches in lymphoma treatment, including:
- Antibody-Drug Conjugates
- Immunotherapy
- Combination Treatment Strategies
Their work involves evaluating novel therapeutic agents and optimizing treatment protocols for various lymphoma subtypes.
Treatment Modalities
The investigator's expertise extends to various treatment administration methods and therapeutic approaches, including:
- Systemic Therapy
- Subcutaneous Administration
- Maintenance Therapy
Their research encompasses both short-term treatment protocols and extended maintenance strategies for optimal patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.